Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 26/10/2020
SIETES contiene 93135 citas

 
 
 1 a 20 de 4411 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Kunchok A, Aksamit Jr AJ, Davis III JM, Kantarci OH, Keegan M, Pittock SJ, Weinshenker BG, McKeon A. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurology 2020:18 de mayo. [Ref.ID 103656]
2. Cita con resumen
Esse S, Mason KJ, Green AC, Warren RB. Melanoma risk in patients treated with biologic therapy for common inflammatory diseases. A systematic review and meta-analysis. JAMA Dermatol 2020:20 de mayo. [Ref.ID 103629]
4. Cita con resumen
Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to infliximab during pregnancy: post-marketing experience. Drug Saf 2020;43:febrero. [Ref.ID 103539]
5. Cita con resumen
Lassalle M, Le Tri L, Bardou M, Biour M, Kirchgesner J, Rouby F, Dumarcet N, Zureik M, Dray-Spira R. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 2020;76:449-57. [Ref.ID 103532]
6. Cita con resumen
Khan R, Nugent CM, Scaffidi MA, Gimpaya N, Grover SC. Association of biologic prescribing for inflammatory bowel disease with industry payments to physicians. JAMA Intern Med 2019;179:8 de julio. [Ref.ID 103170]
7.Enlace a cita original Cita con resumen
Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]
8. Cita con resumen
Anónimo. Clozapine ou autres neuroleptiques: occlusions intestinales mortelles. Prescrire 2018;38:511. [Ref.ID 102760]
9. Cita con resumen
Anónimo. Nétupitant + palonosétron et prévention des vomissements chimio-induits. Prescrire 2018;38:176-7. [Ref.ID 102587]
10. Cita con resumen
Anónimo. Éluxadoline et troubles fonctionnels intestinaux récurrents. Prescrire 2018;38:91-5. [Ref.ID 102580]
11.Enlace a cita original Cita con resumen
Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, Myint PK, Grossi CM, Mattishent K, Bennett K, Campbell NL, Boustani M, Robinson L, Brayne C, Matthews FE, Savva GM. Anticholinergic drugs and risk of dementia: case-control study. BMJ 2018;361:25 de abril. [Ref.ID 102571]
12.Enlace a cita original Cita con resumen
Abrahami D, Douros A, Yin H, Yu OHY, Renoux C, Bitton A, Azoulay L. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018;360:21 de marzo. [Ref.ID 102562]
13.Enlace a cita original Cita con resumen
Bonovas S, Nikolopoulos GK, Lytras T, Fiorino G, Peyrin-Biroulet L, Danese S. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis . Br J Clin Pharmacol 2018;84:febrero. [Ref.ID 102533]
14. Cita con resumen
Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurology 2017:5 de septiembre. [Ref.ID 102058]
15. Cita con resumen
Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med 2017;177:1308-15. [Ref.ID 102042]
16. Cita con resumen
Anónimo. Ivacaftor et mucoviscidose (suite). Prescrire 2017;37:566-8. [Ref.ID 102040]
17. Cita con resumen
Anónimo. Ivacaftor + lumacaftor et mucoviscidose. Prescrire 2017;37:569-71. [Ref.ID 102039]
18. Cita con resumen
Wallerstedt SM, Fastbom J, Linke J, Vitols S. Long-term use of proton pump inhibitors and prevalence of disease - and drug-related reasons for gastroprotection — A cross-sectional population-based study. Pharmacoepidemiol Drug Saf 2017;26:9-16. [Ref.ID 101946]
19. Cita con resumen
Wei L, Ratnayake L, Phillips G, McGuigan CC, Morant SV, Flynn RW, Mackenzie IS, MacDonald TM. Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study. Br J Clin Pharmacol 2017;83:1298-308. [Ref.ID 101942]
20. Cita con resumen
Persson M, Cnattingius S, Villamor E, Söderling J, Pasternak B, Stephansson O, Neovius M. Risk of major congenital malformations in relation to maternal overweight and obesity severity: cohort study of 1.2 million singletons. BMJ 2017;357:j2563. [Ref.ID 101639]
Seleccionar todas
 
 1 a 20 de 4411 siguiente >>